Effects of Daratumumab(dara), Cyclophosphamide (C), Thalidomide (T) and Dexamethasone (D) Combination on Lymphocyte Populations of Transplant Eligible Newly Diagnose Multiple Myeloma Patients

被引：0
|
作者：
Santos, Allan [1 ]
Santos, Herbert [2 ]
Leal, Joanna [3 ]
Santos, Juliana [2 ,3 ]
Salvino, Marco [4 ]
Lucas, Larissa [3 ]
Santos, Mariane [1 ]
Hungria, Vania T. M. [5 ]
Torres, Alex [6 ]
Crusoe, Edvan de Queiroz [7 ]
机构：
[1] Univ Fed Bahia, Immunol & Cytometry Lab, Salvador, BA, Brazil
[2] Univ Fed Bahia, Salvador, BA, Brazil
[3] Oncol DOr BA Brazil, Salvador, BA, Brazil
[4] Univ Fed Bahia, Bone Marrow Transplantat unit, Salvador, BA, Brazil
[5] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil
[6] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil
[7] Rede Dor Oncol, Salvador, BA, Brazil
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-244
引用
收藏
页码：S178 / S179
页数：2
相关论文
共 50 条
  • [31] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure
    Moore, Donald C.
    Arnall, Justin R.
    Janes, Amanda
    Pineda-Roman, Mauricio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07): : E395 - E398
  • [33] CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (CTD) AS INITIAL THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Vasquez, J.
    Ruiz, R.
    Aliaga, K.
    Valencia, F.
    Enriquez, D.
    Palacios, V.
    Quintana, S.
    Casanova, L.
    HAEMATOLOGICA, 2016, 101 : 798 - 798
  • [34] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma
    Jimenez-Zepeda, Victor
    Bahlis, Nizar J.
    Duggan, Peter
    Alonso, Rafael
    Lahuerta, Juan Jose
    Valeri, Antonio
    Neri, Paola
    Tay, Jason
    Martinez-Lopez, Joaquin
    BLOOD, 2016, 128 (22)
  • [35] Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Sauer, Sandra
    Kriegsmann, Katharina
    Nientiedt, Cathleen
    Schmitt, Anita
    Mueller-Tidow, Carsten
    Raab, Marc-Steffen
    Kauer, Joseph
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2023, 50 (05) : 371 - 380
  • [36] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
    Sonneveld, Pieter
    Attal, Michel
    Perrot, Aurore
    Hulin, Cyrille
    Caillot, Denis
    Facon, Thierry
    Leleu, Xavier
    Belhadj-Merzoug, Karim
    Karlin, Lionel
    Benboubker, Lofti
    Levin, Mark-David
    Minnema, Monique
    Westerman, Matthijs
    Delforge, Michel
    Zweegman, Sonja
    Pei, Lixia
    de Boer, Carla
    Vanquickelberghe, Veronique
    Kampfenkel, Tobias
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E3
  • [37] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Shune, Leyla
    Badros, Ashraf
    Chari, Ajai
    Richardson, Paul G.
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Hoehn, Daniela
    Lin, Thomas S.
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309
  • [38] Efficacy of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.
    Avet-Loiseau, Herve
    Moreau, Philippe
    Attal, Michel
    Hulin, Cyrille
    Arnulf, Bertrand
    Corre, Jill
    Garderet, Laurent
    Karlin, Lionel
    Lambert, Jerome
    Macro, Margaret
    Perrot, Aurore
    Sonneveld, Pieter
    Levin, Mark-David
    Klein, Saskia
    Chiu, Christopher
    Pei, Lixia
    De Boer, Carla
    Kampfenkel, Tobias
    Wuilleme, Soraya
    Bene, Marie-Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Clinical outcomes of transplant-eligible multiple myeloma patients treated with frontline thalidomide/dexamethasone
    Ha, H.
    Youk, J.
    Park, H.
    Lee, J. -O
    Bang, S. -M.
    Kim, K-H.
    Park, J. -H.
    Koh, Y.
    Kim, I.
    Yoon, S. -S.
    Park, S.
    BONE MARROW TRANSPLANTATION, 2015, 50 : 5626 - 5627
  • [40] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
    Mehra, Maneesha
    Cote, Sarah
    Kampfenkel, Tobias
    Nair, Sandhya
    BLOOD, 2019, 134
12345